BMRN Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 16.72% compared to Biomarin Pharmaceutical's net margin of 23.56%. Biomarin Pharmaceutical's return on equity of 8.09% beat Gilead Sciences's return on equity of 2.5%.

Biomarin Pharmaceutical has a consensus price target of $96.77, signalling upside risk potential of 73.14%. On the other hand Gilead Sciences has an analysts' consensus of $111.67 which suggests that it could grow by 8.22%. Given that Biomarin Pharmaceutical has higher upside potential than Gilead Sciences, analysts believe Biomarin Pharmaceutical is more attractive than Gilead Sciences.

Biomarin Pharmaceutical has a beta of 0.302, which suggesting that the stock is 69.812% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3% to investors and pays a quarterly dividend of $0.79 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $747.3M, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Biomarin Pharmaceutical's net income of $124.9M is lower than Gilead Sciences's net income of $1.8B. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 25.40x while Gilead Sciences's PE ratio is 278.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.89x versus 4.51x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 16.72% compared to Biomarin Pharmaceutical's net margin of -117.16%. Biomarin Pharmaceutical's return on equity of 8.09% beat Moderna's return on equity of -29.09%.

Biomarin Pharmaceutical has a consensus price target of $96.77, signalling upside risk potential of 73.14%. On the other hand Moderna has an analysts' consensus of $52.35 which suggests that it could grow by 112.47%. Given that Moderna has higher upside potential than Biomarin Pharmaceutical, analysts believe Moderna is more attractive than Biomarin Pharmaceutical.

Biomarin Pharmaceutical has a beta of 0.302, which suggesting that the stock is 69.812% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $747.3M, which are smaller than Moderna quarterly revenues of $956M. Biomarin Pharmaceutical's net income of $124.9M is higher than Moderna's net income of -$1.1B. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 25.40x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.89x versus 2.99x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 16.72% compared to Biomarin Pharmaceutical's net margin of 24.16%. Biomarin Pharmaceutical's return on equity of 8.09% beat Sarepta Therapeutics's return on equity of 20.83%.

Biomarin Pharmaceutical has a consensus price target of $96.77, signalling upside risk potential of 73.14%. On the other hand Sarepta Therapeutics has an analysts' consensus of $159.96 which suggests that it could grow by 226.04%. Given that Sarepta Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than Biomarin Pharmaceutical.

Biomarin Pharmaceutical has a beta of 0.302, which suggesting that the stock is 69.812% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $747.3M, which are larger than Sarepta Therapeutics quarterly revenues of $658.4M. Biomarin Pharmaceutical's net income of $124.9M is lower than Sarepta Therapeutics's net income of $159M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 25.40x while Sarepta Therapeutics's PE ratio is 21.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.89x versus 2.89x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 16.72% compared to Biomarin Pharmaceutical's net margin of 31.35%. Biomarin Pharmaceutical's return on equity of 8.09% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Biomarin Pharmaceutical has a consensus price target of $96.77, signalling upside risk potential of 73.14%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.94 which suggests that it could grow by 5.39%. Given that Biomarin Pharmaceutical has higher upside potential than Vertex Pharmaceuticals, analysts believe Biomarin Pharmaceutical is more attractive than Vertex Pharmaceuticals.

Biomarin Pharmaceutical has a beta of 0.302, which suggesting that the stock is 69.812% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $747.3M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Biomarin Pharmaceutical's net income of $124.9M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 25.40x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.89x versus 11.12x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.